Literature DB >> 29955866

Reasons for Opioid Discontinuation and Unintended Consequences Following Opioid Discontinuation Within the TOPCARE Trial.

Jawad M Husain1,2, Marc LaRochelle3,2, Julia Keosaian3,2, Ziming Xuan2,4, Karen E Lasser3,2,4, Jane M Liebschutz2,5.   

Abstract

OBJECTIVE: To identify reasons for opioid discontinuation and post-discontinuation outcomes among patients in the Transforming Opioid Prescribing in Primary Care (TOPCARE) study.
DESIGN: In TOPCARE, an intervention to improve adherence to opioid prescribing guidelines, randomized intervention primary care providers (PCPs) received nurse care manager support, an electronic registry, academic detailing, and electronic tools, and control PCPs received electronic tools only.
SETTING: Four Boston safety net primary care practices.
SUBJECTS: Patients in both TOPCARE study arms who discontinued opioid therapy during the trial.
METHODS: Through chart review, we examined the reason for discontinuation and post-discontinuation outcomes: one or more PCP visits, one or more pain-related emergency department (ED) visits, evidence of opioid use disorder (OUD), and referral for OUD treatment.
RESULTS: Opioid discontinuations occurred in 83/586 (14.2%) intervention and 42/399 (10.5%) control patients (P = 0.09). Among patients who discontinued opioids, 81 (65%) discontinued for misuse, with no difference by group (P = 0.38). Aberrancy in monitoring (e.g., discordant urine drug test results) was the most common type of misuse prompting discontinuation (occurring in (51/83 [61%] of intervention patients vs 19/42 [45%, P = 0.08] of control patients). Intervention patients who discontinued opioids had less PCP follow-up (65% vs 88%, P < 0.01) compared with control patients. We found no differences between groups for pain-related ED visits, evidence of OUD, or OUD treatment referral following discontinuation.
CONCLUSIONS: The decreased follow-up among TOPCARE intervention patients who discontinued opioids highlights the need to understand unintended consequences of involuntary opioid discontinuations resulting from interventions to reduce opioid risk.
© 2018 American Academy of Pain Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Chronic Pain; Discontinuation; Discontinuing; Opioids; TOPCARE; Taper

Year:  2019        PMID: 29955866      PMCID: PMC6611524          DOI: 10.1093/pm/pny124

Source DB:  PubMed          Journal:  Pain Med        ISSN: 1526-2375            Impact factor:   3.750


  15 in total

1.  Effect of abuse-deterrent formulation of OxyContin.

Authors:  Theodore J Cicero; Matthew S Ellis; Hilary L Surratt
Journal:  N Engl J Med       Date:  2012-07-12       Impact factor: 91.245

2.  Improving Adherence to Long-term Opioid Therapy Guidelines to Reduce Opioid Misuse in Primary Care: A Cluster-Randomized Clinical Trial.

Authors:  Jane M Liebschutz; Ziming Xuan; Christopher W Shanahan; Marc LaRochelle; Julia Keosaian; Donna Beers; George Guara; Kristen O'Connor; Daniel P Alford; Victoria Parker; Roger D Weiss; Jeffrey H Samet; Julie Crosson; Phoebe A Cushman; Karen E Lasser
Journal:  JAMA Intern Med       Date:  2017-09-01       Impact factor: 21.873

3.  Trends in opioid analgesic abuse and mortality in the United States.

Authors:  Richard C Dart; Hilary L Surratt; Theodore J Cicero; Mark W Parrino; S Geoff Severtson; Becki Bucher-Bartelson; Jody L Green
Journal:  N Engl J Med       Date:  2015-01-15       Impact factor: 91.245

Review 4.  Relationship between Nonmedical Prescription-Opioid Use and Heroin Use.

Authors:  Wilson M Compton; Christopher M Jones; Grant T Baldwin
Journal:  N Engl J Med       Date:  2016-01-14       Impact factor: 91.245

5.  Trends in Opioid Analgesic-Prescribing Rates by Specialty, U.S., 2007-2012.

Authors:  Benjamin Levy; Leonard Paulozzi; Karin A Mack; Christopher M Jones
Journal:  Am J Prev Med       Date:  2015-04-18       Impact factor: 5.043

6.  National trends in long-term use of prescription opioids.

Authors:  Ramin Mojtabai
Journal:  Pharmacoepidemiol Drug Saf       Date:  2017-09-06       Impact factor: 2.890

7.  Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial.

Authors:  Erin E Krebs; Amy Gravely; Sean Nugent; Agnes C Jensen; Beth DeRonne; Elizabeth S Goldsmith; Kurt Kroenke; Matthew J Bair; Siamak Noorbaloochi
Journal:  JAMA       Date:  2018-03-06       Impact factor: 56.272

8.  Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain.

Authors:  Roger Chou; Gilbert J Fanciullo; Perry G Fine; Jeremy A Adler; Jane C Ballantyne; Pamela Davies; Marilee I Donovan; David A Fishbain; Kathy M Foley; Jeffrey Fudin; Aaron M Gilson; Alexander Kelter; Alexander Mauskop; Patrick G O'Connor; Steven D Passik; Gavril W Pasternak; Russell K Portenoy; Ben A Rich; Richard G Roberts; Knox H Todd; Christine Miaskowski
Journal:  J Pain       Date:  2009-02       Impact factor: 5.820

9.  Substance Use Disorder Treatment Following Clinician-Initiated Discontinuation of Long-Term Opioid Therapy Resulting from an Aberrant Urine Drug Test.

Authors:  Shannon M Nugent; Steven K Dobscha; Benjamin J Morasco; Michael I Demidenko; Thomas H A Meath; Joseph W Frank; Travis I Lovejoy
Journal:  J Gen Intern Med       Date:  2017-06-09       Impact factor: 5.128

Review 10.  CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016.

Authors:  Deborah Dowell; Tamara M Haegerich; Roger Chou
Journal:  JAMA       Date:  2016-04-19       Impact factor: 56.272

View more
  3 in total

1.  Associations of opioid prescription dose and discontinuation with risk of substance-related morbidity in long-term opioid therapy.

Authors:  Patrick D Quinn; Zheng Chang; Matthew J Bair; Martin E Rickert; Robert D Gibbons; Kurt Kroenke; Brian M D'Onofrio
Journal:  Pain       Date:  2022-04-01       Impact factor: 7.926

2.  Decreasing risk among HIV patients on opioid therapy for chronic pain: Development of the TOWER intervention for HIV care providers.

Authors:  Jessica Robinson-Papp; Judith Aberg; Emma K T Benn; Angela Bryan; Gabriela Cedillo; Yosuke Chikamoto; Mary Catherine George; Brady Horn; Alexandra Kamler; Allison Navis; Alexandra Nmashie; Maya Scherer; Angela Starkweather; Barbara Vickrey; Linda Weiss; Qiuchen Yang; Jeffrey Fisher
Journal:  Contemp Clin Trials Commun       Date:  2019-10-12

3.  Trajectories of prescription opioid dose and risk of opioid-related adverse events among older Medicare beneficiaries in the United States: A nested case-control study.

Authors:  Yu-Jung Jenny Wei; Cheng Chen; Motomori O Lewis; Siegfried O Schmidt; Almut G Winterstein
Journal:  PLoS Med       Date:  2022-03-15       Impact factor: 11.613

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.